Latest news with #LarryBiegelsen
Business Insider
30-05-2025
- Business
- Business Insider
Goldman Sachs Sticks to Their Hold Rating for Tandem Diabetes Care (TNDM)
In a report released yesterday, from Goldman Sachs maintained a Hold rating on Tandem Diabetes Care (TNDM – Research Report). The company's shares closed yesterday at $21.28. Confident Investing Starts Here: In addition to Goldman Sachs, Tandem Diabetes Care also received a Hold from Wells Fargo's Larry Biegelsen in a report issued on May 28. However, on May 20, Lake Street maintained a Buy rating on Tandem Diabetes Care (NASDAQ: TNDM). TNDM market cap is currently $1.43B and has a P/E ratio of -7.60. Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year. Most recently, in March 2025, Jean-Claude Kyrillos, the EVP & COO of TNDM bought 10,538.00 shares for a total of $190,948.56.
Business Insider
11-05-2025
- Business
- Business Insider
Analysts Turn Bullish on Insulet Stock (PODD) after Strong Q1 Earnings
Insulet Corporation (PODD), the healthcare company known for its insulin delivery system, has experienced a phenomenal week, encapsulated in its stock soaring almost 21% on Friday. It came after the company delivered a standout Q1 2025 performance, driving bullish sentiment from top Wall Street analysts. The company reported a 30% year-over-year revenue jump to $569 million, fueled by strong Omnipod sales and rapid international expansion. Gross margin climbed to 71.9%, a 240-basis-point improvement, reflecting operational efficiency gains. With rising demand in the type 2 diabetes market – now accounting for over 30% of new U.S. customers – and a successful global rollout of Omnipod 5, Insulet raised its full-year guidance, projecting company revenue growth between 19% and 22%. Protect Your Portfolio Against Market Uncertainty Analysts Are Bullish Following the results, Insulet's stock soared, reflecting investor optimism about its sustained momentum and market penetration strategy. This impressive run was echoed by analysts, with both Wells Fargo and Oppenheimer reiterating Buy ratings and increasing their price targets. Oppenheimer's five-star analyst, Steven Lichtman, raised his target from $312 to $324, suggesting an upside of 4.29%. Meanwhile, Wells Fargo's five-star analyst, Larry Biegelsen, went further, lifting his target from $322 to $330, suggesting a 6.22% upside potential. Morgan Stanley's (MS) Patrick Wood also joined the bullish choir. He reiterated his Buy rating on Insulet and a price target of $325, suggesting a 4.61% upside. He highlighted strong U.S. and international growth, especially in type 2 diabetes adoption, and a notable margin beat, signaling operational efficiency. Another was William Blair's Margaret Kaczor, who maintained a Buy rating, citing Insulet's Q1 sales beat and raising full-year guidance. Most Wall Street analysts generally see PODD's leadership under new CEO Ashley McEvoy as a positive development in expanding the company's reach and capitalizing on the substantial growth opportunity in the global insulin pump market. Wall Street is highly bullish on Insulet Corporation with a Strong Buy rating. The average price target for PODD stock is $321.88, suggesting a 3.61% upside potential.
Yahoo
30-01-2025
- Business
- Yahoo
Intuitive Surgical, Inc. (ISRG): Pioneering Robotic-Assisted AI-Driven Surgeries
We recently published a list of . In this article, we are going to take a look at where Intuitive Surgical, Inc. (NASDAQ:ISRG) stands against other top AI stocks that are being monitored by Wall Street. As the global tech sector was catching up to the disruption caused by DeepSeek's r1 AI model, Chinese e-commerce giant Alibaba announced its brand new Qwen 2.5 AI model on the first day of the Lunar New Year. The Qwen 2.5 is pre-trained on large-scale multilingual and multimodal data and rivals DeepSeek's AI model. 'Qwen 2.5-Max outperforms … almost across the board GPT-4o, DeepSeek-V3 and Llama-3.1-405B,' the group's cloud unit on its official WeChat account. The latest Chinese AI model release also sent US firms scrambling to innovate and stay ahead of the competition. OpenAI CEO Sam Altman recently teased several 'exciting new features' coming to ChatGPT and a new ChatGPT Gov tool to bolster ties with the US government. The rise of advanced, cost-effective Chinese AI models has introduced volatility in US stocks as analysts rampantly rerate companies and shift outlooks based on the rapidly evolving tech landscape. We selected AI stocks by reviewing news articles, stock analysis, and press releases. We listed the stocks in ascending order of their hedge fund sentiment taken from Insider Monkey's database of 900 hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (). A medical team performing minimally invasive surgery with a da Vinci Surgical System. Intuitive Surgical, Inc. (NASDAQ:ISRG) designs and builds cutting-edge robotic-assisted surgical systems. The company uses AI to refine its robotic systems, including the da Vinci Surgical System, to help surgeons carry out minimally invasive surgeries with higher precision for improved patient outcomes. Intuitive Surgical (NASDAQ:ISRG) also uses AI in real time to help clinicians predict patients' risk of developing surgical complications with higher accuracy. On January 29th, Wells Fargo analyst Larry Biegelsen noted Intuitive Surgical, Inc.'s (NASDAQ:ISRG) lawsuit win yesterday versus emerging competitor Surgical Instrument Service, which might translate to a win for the company in the class action lawsuit, given that the cases are similar and are being heard by the same judge. Surgical Instrument Service accused Intuitive Surgical, Inc. (NASDAQ:ISRG) of breaching antitrust law by illegally preventing its customers from purchasing the company's 'repaired' EndoWrists. The analysts believe the case is vital because it is a preview of the substance in the bigger class action case, considering that the case moves forward. Based on yesterday's positive outcome, the brokerage retained its 'Overweight' rating for Intuitive Surgical, Inc. (NASDAQ:ISRG) with a $687 stock price target. Overall, ISRG ranks 5th on our list of top AI stocks that are being monitored by Wall Street. While we acknowledge the potential of ISRG as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ISRG but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
